Clinical Hours: Mon-Fri, 8AM - 3PM(905) 493-5700
1885 Glenanna Road, Suite 220, Pickering, ON, L1V 6R6
The story of botulinum toxin runs from nineteenth-century sausage poisoning to modern dermatology, where it treats excessive sweating, scars, and oily skin, well beyond smoothing wrinkles.
Few substances in medicine carry a stranger biography than botulinum toxin. It begins as one of the most poisonous natural substances known, the agent behind a lethal form of food poisoning traced to spoiled sausages in nineteenth-century Germany, and it arrives, two centuries later, as a precise therapeutic tool used across dermatology and neurology. The same molecule that once paralysed and killed is now injected in minute, purified doses to calm overactive sweat glands, soften scars, and ease chronic pain. The transformation echoes an earlier one, in which the disease behind vampire folklore became a modern skin-cancer treatment.
The word botulism comes from botulus, the Latin term for sausage. During the late eighteenth and early nineteenth centuries, outbreaks of a paralysing, often fatal illness followed the consumption of improperly preserved sausages and smoked meats across the Kingdom of Wurttemberg in southern Germany. Between 1817 and 1822, the German physician and poet Justinus Kerner published the first detailed clinical descriptions of this sausage poisoning, carefully cataloguing the drooping eyelids, blurred vision, dry mouth, and progressive muscle weakness that characterised it [1].
Kerner went further than description. Through animal experiments and self-experimentation, he deduced that the poison acted by interrupting the signals sent to the muscles, and, remarkably, he speculated that a carefully measured dose might one day be used to treat conditions of muscular overactivity [1]. That prediction preceded any therapeutic use by more than a century. The responsible organism was not identified until 1897, when the Belgian bacteriologist Emile van Ermengem, investigating a botulism outbreak that had struck mourners at a funeral in the village of Ellezelles, isolated the bacterium now called Clostridium botulinum [2].
Clostridium botulinum produces several related neurotoxins, of which type A is the most widely used in medicine. The toxin acts by cleaving a protein called SNAP-25, a component of the machinery that nerve endings use to release acetylcholine, the chemical messenger that instructs muscles to contract and certain glands to secrete [2]. When acetylcholine release is blocked, the target tissue is temporarily switched off, a state described as chemodenervation.
Two features make this dangerous poison suitable for clinical use. The effect is local, because the toxin acts only where it is injected, and it is reversible, because nerve terminals gradually regenerate their signalling machinery over roughly three to six months. Purified into standardised, minute quantities measured in units rather than milligrams, botulinum toxin type A is transformed from a cause of mass poisoning into a controllable, short-acting medicine.
The first deliberate therapeutic use came not in dermatology but in ophthalmology. During the 1970s and 1980s, the American ophthalmologist Alan Scott tested botulinum toxin type A as a non-surgical way to correct strabismus, or misaligned eyes, by selectively weakening the eye muscles. The cosmetic application that later made the toxin a household name was discovered through careful observation. Working in Vancouver, the ophthalmologist Jean Carruthers noticed that patients treated around the eyes for muscle spasm also lost their frown lines, and, together with her husband, the dermatologist Alastair Carruthers, she reported in 1992 that injection of the toxin smoothed the glabellar frown lines between the eyebrows [3].
That Canadian observation reframed the toxin as a treatment for the muscular cause of expression lines rather than as a filler for the lines themselves. Regulatory approval for the cosmetic treatment of glabellar lines followed in the early 2000s. Yet wrinkle reduction is only the most visible chapter of a much broader dermatological story, one built on the same ability to switch off cholinergic nerve signals, this time to the glands and small muscles of the skin.
Sweat glands are an almost ideal target. Eccrine sweat glands are controlled by sympathetic nerves that, unusually, release acetylcholine, the very messenger that botulinum toxin blocks. In primary focal hyperhidrosis, a common condition in which the underarms, palms, soles, or face sweat far beyond any need for temperature regulation, this mechanism makes the toxin highly effective [4].
Supported: in a controlled trial published in the New England Journal of Medicine, injection of botulinum toxin type A into the underarms substantially reduced sweat production and improved quality of life, with benefits typically lasting several months per treatment [4]. Regulatory approval for severe primary axillary hyperhidrosis followed in 2004. Palmar hyperhidrosis, which can interfere with writing, tools, and social contact, also responds well, although injections into the hand demand attention to grip strength and are frequently combined with local anaesthesia. For patients whose sweating has not responded to prescription antiperspirants, botulinum toxin is one of several established options.
Interest in botulinum toxin for scarring grows from a different mechanism. Keloid and hypertrophic scars form when wound healing produces excess collagen, a process influenced by mechanical tension across the healing edges and by signalling molecules such as transforming growth factor beta. By relaxing the small muscles that pull on a wound and reducing that tension, and possibly by acting directly on the fibroblasts that manufacture collagen, the toxin may steer healing toward a flatter, softer scar.
The caveats: the evidence remains early and mixed. A randomized controlled trial found intralesional botulinum toxin type A to be as effective as, and better tolerated than, intralesional corticosteroid in the treatment of keloids [5], and a systematic review and meta-analysis reported greater improvement in scar height, pliability, and symptoms with the toxin than with corticosteroid or placebo [6]. These findings are encouraging rather than definitive. Botulinum toxin is best regarded as one part of a scar-management plan that may also include intralesional steroid injections, pressure, silicone, and, where appropriate, surgical scar revision.
A newer application targets the surface quality of the skin rather than the muscles beneath it. When very small amounts of dilute botulinum toxin are placed into the superficial dermis as multiple microdroplets, an approach often called microbotox or intradermal microdosing, the sebaceous glands and the tiny arrector pili muscles around the hair follicles are partially quietened. Because sebaceous glands also respond to cholinergic signalling, the result can be a measurable reduction in oil production and in the visible size of enlarged pores.
A randomized, double-blinded, placebo-controlled study of intradermal botulinum toxin type A reported reduced sebum secretion in treated skin [7], and a clinical review of intradermal microdosing describes improvements in pore size, oiliness, and overall skin texture, while stressing that the effects are subtle and temporary [8]. This use is best understood as refinement of skin quality rather than a treatment for active acne, and it does not replace established therapies for oily or acne-prone skin.
Botulinum toxin has also been studied for pattern hair loss, on the theory that relaxing the scalp muscles increases local blood flow and lowers the conversion of testosterone to dihydrotestosterone, the hormone central to androgenetic alopecia. The idea is biologically plausible, and several small early studies reported gains in hair count [9].
Overstated: the strongest evidence tempers this enthusiasm. A systematic review concluded that most supporting studies were small and methodologically limited [9], and a more recent triple-blind, randomized clinical trial that used precise hair-counting technology found no significant benefit of botulinum toxin over placebo in men with androgenetic alopecia [10]. At present, botulinum toxin is not an established treatment for hair loss, and proven options such as topical and oral therapies remain the foundation of care.
The dermatological uses sit within a still wider therapeutic range. The broader clinical applications of botulinum toxin include a number of neurological and muscular disorders, such as cervical dystonia, limb spasticity, and blepharospasm, all of which reflect the same core action of dialling down overactive nerve-to-muscle signalling. In 2010, following two large randomized trials in the PREEMPT program, onabotulinumtoxinA was approved for the prevention of chronic migraine, a use in which repeated injections across the head and neck reduced the number of headache days [11].
The arc of botulinum toxin is a reminder that the line between poison and medicine is often a matter of dose, purity, and intention. A substance that once spread through spoiled sausages and threatened lives is now delivered in fractions of a unit to calm a sweating palm, soften a scar, or prevent a migraine. Its dermatological value lies not in a single dramatic effect but in the precision with which one well-understood mechanism can be directed at very different problems.
Not every proposed use is equally proven. The evidence for excessive sweating is strong, the evidence for scars is promising, and the evidence for hair loss remains unsettled. For anyone weighing treatment, an assessment with a dermatologist can clarify which applications are supported for a given concern and whether botulinum toxin, alone or alongside other therapies, is an appropriate choice. Booking a consultation is the first step toward that individualised plan.
This article is intended for educational purposes and does not replace professional medical advice. Please consult your dermatologist for personalized recommendations.
Your feedback helps us improve our news and clinical insights
From medical dermatology to surgical procedures, our clinic provides comprehensive care for all skin, hair, and nail conditions.